Bauer U. Six-month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung [Drug Research] 1984;34:716–20.

Braquet P, Spinnewyn B, Braquet M, et al. BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from the Ginkgo biloba. Blood Vessels 1985;16:559 –572.

Bruchert E, Heinrich SE, Ruf-Kohler P. Wirsamkeit von LI1370 bei alteren Patienten mit Hirnleistungsschwache Multizentrische Doppelblindstudie des Fachverbandes deutscher Allgemeinzartze. Munchener Medizinische Wochenschrift 1991;133:S9–S14.

Bundes A. Ginkgo biloba leaves: Bundes Anzeiger, 1994.

Chiu C-P, Hsieh K-H. Pulmonary response to platelet-activating factor (PAF) and PAF antagonist BN 52021 in allergic asthmatic children. In: Braquet P, ed. Ginkgolides-Chemistry, Biology, Pharmacology and Clinical Perspectives Barcelona, Spain: J. R. Prous Science Publishers, S. A., 1989;877– 878.

DeFeudis F. Ginkgo biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris: Elsevier, 1991.

Ernst E, Pittler MH. Ginkgo biloba for dementia: A systematic review of double-blind, placebo-controlled trails. Clinical Drug Investigation 1999;4:301-308.

Grunwald J. The European phytomedicines market: figures, trends, analyses. Herbal Gazette 1995;34:60–65.

Guinot P. Tanakan inhibits platelet-activating aggregation in healthy male volunteers. Homeostasis 1989;19:219–223.

Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1A receptors during aging: Reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol 1994;46:316–8.

Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34:352–8.

Kose K, Dogan P. Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes. 1. Protective effect of Ginkgo biloba extract (EGb 761). J Int Med Res 1995;23:1– 8.

LeBars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–32.

Lebuisson DA, Leroy L, Rigal G. Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary doubleblind drug versus placebo study. Presse Med 1986;15:1556–8.

Li CL, Wong YY. The Bioavailability of Ginkgolides in Ginkgo biloba Extracts. Planta Medica 1997;63:563–5.

Maitra I, Marocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract (EGb 761). Biochem Pharmacol 1995; 49:1649 –55.

Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardes-Albert M. Antioxidant action of Ginkgo biloba extract (EGb 761). Methods Enzymol 1994;234:462–75.

Maruyama, M.; Terahara, A.; Itagaki, Y.; Nakanishi, K. The Structure of Ginkgolides. Tetrahedron Lett 1967;1:299, 303, 315, 321.

Pincemail J, Dupuis M, Nasr C, et al. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 1989;45:708 –12.

Schmidt U, Rabinovici K, Lande S. Einfluss eines Ginkgo-biloba-Spezialextraktes auf die Befindlichkeit bei cerebraler Insuffizienz. Munchener Medizinische Wochenschrift 1988;133:S15–S18.

Sticher, O. Quality of Ginkgo preparations. Planta Medica 1993;59:2–11.